Home › Categories › Science & Nature› First-in-Human Study Of MT-6402, A PD-L1 Targeting Engineered Toxin Body, In Patients With Relapsed Or Refractory Advanced Solid Tumors

First-in-Human Study Of MT-6402, A PD-L1 Targeting Engineered Toxin Body, In Patients With Relapsed Or Refractory Advanced Solid Tumors.pdf

SITC 7641.pdf
Preview of First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors
🔗 Source: d1io3yog0oux5.cloudfront.net
📊 Size: 1.08 MB
👤 Author: Lisa Greaves
⬇️ Downloads: 366

Summary

An Engineered Toxin Body Targeting PD-L1

This interim analysis presents a first-in-human study of MT-6402, an engineered toxin body (ETB) designed to target programmed death-ligand 1 (PD-L1) in patients with advanced solid tumors. The study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of MT-6402.

## Key Points:
- Study Design: A phase 1 dose escalation and expansion trial involving 19 patients with PD-L1 expressing tumors.
- Dose Escalation: Patients were divided into cohorts receiving different doses (16 µg/kg, 24 µg/kg, 32 µg/kg, and 42 µg/kg).
- Safety: The most common treatment-related adverse events (AEs) included anemia, back pain, cough, dyspnea, fever, and nausea. No severe toxicities (grade 4 or 5 AEs) were observed.
- Pharmacokinetics: MT-6402 demonstrated consistent exposure across doses, with no accumulation after repeat dosing. Anti-drug antibodies developed in all patients.
- Pharmacodynamics: The drug effectively reduced PD-L1 positive peripheral monocytes and dendritic cells, depleted myeloid-derived suppressor cells (MDSCs), and shifted T cell phenotypes towards effector states.
- Efficacy: One patient with a high PD-L1 tumor expression level experienced a response after dose reduction due to grade 2 cytokine release syndrome (CRS). Biopsies showed changes in the tumor microenvironment associated with clinical response.
- Future Plans: Expansion cohorts are planned, focusing on specific populations based on HLA status, CMV status, and PD-L1 tumor expression levels.

Download File

Description

Document en en

Technical Information

  • File Format: PDF
  • File Size: 1.08 MB
  • Pages: 1
  • Language: EN
  • Author: Lisa Greaves
  • Total Downloads: 366
  • Last Updated: 1 month ago

Document Overview

This PDF document about First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors.

Related Topics

If you're interested in First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors, you might also want to explore:

First-in-Human guideFirst-in-Human tutorialStudy guideStudy tutorialMT-6402, guideMT-6402, tutorialPD-L1 guidePD-L1 tutorialTargeting guideTargeting tutorialEngineered guideEngineered tutorialToxin guideToxin tutorialBody, guideBody, tutorialPatients guidePatients tutorialwith guidewith tutorialRelapsed guideRelapsed tutorialRefractory guideRefractory tutorialAdvanced guideAdvanced tutorialSolid guideSolid tutorialTumors guideTumors tutorial

Related Categories

Business & Finance
41204 documents
Education & Learning
22711 documents
Health & Wellness
8956 documents
Technology
4783 documents

Related Documents

Preview of Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
PDF file

Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

94 KBEN7 pages
Molecular Templates, Inc. shifts focus to clinical development of key drugs (MT-6402, MT-8421, MT-0169) and preclinical BMS collaboration, downsizing...
Download
Preview of ONCOS-102 Therapy
PDF file

ONCOS-102 Therapy

1.28 MBPekka SimulaEN16 pages
ONCOS-102 is a genetically modified oncolytic adenovirus encoding GM-CSF, replicating in cancer cells and inducing immunogenic cell death.
Download
Preview of SM 6000 Manual
PDF file

SM 6000 Manual

117 KBadminEN1 page
The SM 6000 is a photoelectric DC thru beam sensor with a variable range of 1-6m, adjustable.
Download
Preview of Human Body Systems
PDF file

Human Body Systems

35 KBEN1 page
The heart pumps blood around the body to deliver oxygen where needed, with its size and function varying depending on the animal's size.
Download
Preview of PDF
PDF file

PDF

547 KBYousif AbdallahEN8 pages
This study investigates how respiration affects the motion of lung and pancreas tumors and its impact on radiotherapy treatment.
Download

Download First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors eBooks for free and learn more about First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors. These books contain exercises and tutorials to improve your practical skills, at all levels!

Not satisfied with this document? We have related documents to First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors, try searching with similar keywords: First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors, Engineered Systems Free Engineered Systems Publica, Apnea Hypopnea Index (AHI) Application in Intensive Care Patients: A Case Study of Eight Patients, Apnea Hypopnea Index Ahi Application In Intensive Care Patients A Case Study Of Eight Patients, 6402 Ericsson , Convert 6402 Cm2 To M2, Marazzi Uf3t Lugano 6402 08, Fatty Tumors In Human Body

You can download PDF versions of the user's guide, manuals and ebooks about First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors, you can also find and download for free A free online manual (notices) with beginner and intermediate, Downloads Documentation, You can download PDF files (or DOC and PPT) about First-in-Human Study of MT-6402, a PD-L1 Targeting Engineered Toxin Body, in Patients with Relapsed or Refractory Advanced Solid Tumors for free, but please respect copyrighted ebooks.